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I. INTRODUCTION 
We remain firmly committed to fulfilling our long-term mission to help people 
everywhere have access to their own genetic data and have the ability to use that 
information to improve their lives.2 
 
  This bold statement made by Anne Wojcicki, co-founder and CEO of 23andMe, a leading 
organization in the direct-to-consumer genetic testing industry, expresses the goals of the current 
genetic revolution.  A market worth more than 8.6 billion dollars has been created based on the 
genetic make up of an individual. Due to advances in genetic science and the completion of the 
Human Genome Project, genetic tests are now being marketed directly to consumers. Private 
companies, such as 23andme, use print, television, and Internet advertising to reach consumers 
within their homes with the promise of identifying health related issues, including the individuals 
potential for disease and future health risks, as well as identifying their ancestral relationships.  
 The direct-to-consumer (“DTC”) genetic testing industry has been flourishing, which has 
caught the attention of federal regulatory agencies due to the rising public health concerns behind 
the validity, safety, and effectiveness of these genetic tests. The Food and Drug Administration 
(“FDA”) and the Centers for Medicare & Medicaid Services (“CMS”) have tried to regulate the 
growing field, but have fell behind.  The industry is now at a standstill since the FDA has sent 
warning letters to numerous companies for violations of the Food, Drug, and Cosmetic Act, 
which prompted a halt to sales of DTC genetic tests. However, the enforcement by the FDA has 
not been clear or transparent, which has left must confusion within the industry. The FDA action 
thus far has caused companies to be left in the dark as to what steps they can take to comply with 
the FDA in order to place their products safely back on the market. The push by the FDA and 
other agencies to regulate DTC genetic tests as medical devices and the push by companies for a 
clear transparent compliance direction is now at the forefront for the industry.  
                                                        
2 23andMe, Health, https://www.23andme.com/health (last visited Dec. 7, 2014). 
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 Part I of this article will look at the history of genetic testing and the evolution of the 
DTC testing industry specifically. It will also analyze the advantages and disadvantages of 
marketing directly to the consumer. Part II examines the current regulatory framework laid out 
by both the FDA and CMS. CMS has the authority to regulate clinical laboratories, which 
includes laboratories that generate genetic tests. However, this does not cover the clinical 
validity of the tests. The FDA has the authority to regulate the validity of all medical devices and 
has strict procedures that must be followed to ensure accuracy and safety. DTC genetic tests 
come to the market for an array of reasons and are falling into the gaps of the unregulated based 
on how they are marketed. An in depth look at the medical device statute and the classification 
system currently used will give insight into how further regulation can be expanded to avoid any 
gaps. Part III of this article will look at FDA enforcement action, as well as comments from other 
agencies that push for regulation of the DTC industry in an effort promote public safety.  
This article will ultimately conclude that in order for the industry to move forward, there 
must be a clear system in place to promote transparency and to ensure safety. Part IV of this 
article will offer the recommendation that the FDA issue clear regulations directed to the DTC 
genetic testing industry. Using a risk-based classification approach, similar to the one currently 
used in the regulation of other medical devices and laboratory developed tests, the FDA can 
protect patient safety while promoting the future of medicine in the United States. This article 
further recommends that the FDA and CMS must work together in order to ensure transparency 
throughout the process. The FDA issuing regulations and CMS creating a genetic testing 
specialty can do this. By filling in the gaps, the genetic testing companies will know the 
necessary steps and take action to act in compliance. Thus, consumers can continue to evolve 
with the science and reap the benefits of genetic testing.  
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II. UNDERSTANDING DIRECT-TO-CONSUMER GENETIC TESTING 
A. History of Genetic Testing 
 The study of genetics began with who is now deemed the father of genetics, Gregory 
Mendel, in the late nineteenth century.3 His work with pea plants led to the fundamental laws of 
inheritance and presented the first conclusion that genes come in pairs and are inherited equally 
one from each parent, passed from generations.4 It was not until well after his death that the 
importance of his work was realized when Hugo de Vries, along with two other researchers, 
discovered Mendel’s principles and published the results.5  Then, in 1869, Frederick Miescher 
identified deoxyribonucleic acid, or DNA, for the first time and in 1905, William Bateson 
denoted the name “genetics” to this evolving branch of scientific study.6 
 With a strong scientific foundation, genetic scientists Dr. James D. Watson and Francis 
Crick discovered the structure of DNA in 1953.7 The duo described the fundamental structure of 
DNA as a double helix.8 The work of Watson and Crick expanded upon those of Mendel in 
determining that the hereditary portions of humans were found within the double helix DNA.9 
Thus, DNA is the molecule carrying our individual genetic codes. This expanded knowledge of 
the structure of the DNA molecule was the key to understanding how genetic information is 
copied and the start of the genetic testing revolution.10   
                                                        
3 M. Tevfik Dorak, Landmarks in the History of Genetics, Dorak.info, http://www.dorak.info/genetics/notes01.html 
(last updated July 14, 2013). 
4 Id. 
5 Id.  
6 Id. 
7 James D. Watson & Francis H.C. Crick, Molecular Structure of Nucleic Acids, 171 NATURE 737, 737 (1953). 
8 Id. at 737-738. 
9 James D. Watson & Francis H.C. Crick, Genetical Implications of the Structure of Deoxyribonucleic Acid, 171 
NATURE 964, 965 (1953). 
10 Leslie A. Pray, Discovery of DNA Structure and Function: Watson and Crick, 1 NATURE EDUC. (2008), available 
at http:// www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-functionwatson-397. 
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 Throughout the twentieth century, scientists developed genetic tests for genetic 
conditions such as Down syndrome, Cystic fibrosis, and Duchene muscular dystrophy.11 In 1990, 
the United States Department of Energy and the National Institutes of Health coordinated the 
Human Genome Project. 12  The project was an international effort to determine the entire 
sequence of the human genome and identify the millions of genes that it contains.13 In 2003, after 
spending millions of dollars, the Human Genome Project was finished and released with the 
completed sequences of the human genome.14 
As a result of the project, scientists have developed genetic tests for more than 2,500 
diseases.15 Virtually all diseases stem in some part from our genetic make-up and genetic tests 
identify changes within genes to find the potential for specific diseases.16 The term ′′genetic test′′ 
has never been defined by FDA or by CMS, but the Federal Advisory Committee has defined it 
as "the analysis of human DNA, RNA, chromosomes, proteins, and certain metabolites in order 
to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical 
purposes.”17 Genetic testing is now ′′a mainstream part of medical care′′ and is used to diagnosis, 
prediction, and detection of genetic diseases in newborns, children, and adults, as well as 
assesses risks to those individuals in the future.18 
                                                        
11 National Inst. of Health, Fact Sheet, Genetic Testing: How it is Used for Healthcare, National Human Genome 
Research Institute, http://www.report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=43&key=G (Oct. 2010). 
12 Human Genome Project, About the Human Genome Project, 
http://web.ornl.gov/sci/techresources/Human_Genome/project/index.shtml (last visited Dec. 7, 2014). 
13 Id.; F. Collins, The Human Genome Project: Lessons from Large-Scale Biology, 300 SCIENCE 286, 286 (2003). 
14 Collins, supra note 13. 
15 Ctrs. For Disease Control & Prevention, Public Health Genomics: Genetic Testing, 
http://www.cdc.gov/genomics/gtesting/ (last updated June 28, 2013). 
16 National Human Genome Research Institute, A Brief Guide to Genomics, http://www.genome.gov/18016863 (last 
visited Dec. 7, 2014). 
17 Neil A. Holtzman & Michael S. Watson, Promoting Safe and Effective Genetic Testing in the United States: Final 
Report of the Task Force on Genetic Testing, Nat’l Insts. of Health (1997), available 
at http://www.genome.gov/10002405 (last visited Dec. 7, 2014); Wylie Burke, Genomic Medicine: Genetic Testing, 
347 NEW ENG. J. MED. 1867, 1867 (2002)(quoting U.S. Task Force on Genetic Testing, Promoting Safe and 
Effective Genetic Testing in the United States (Neil A. Holtzman & Michael S. Watson eds., 1997)). 
18 Gail H. Javitt, In Search of a Coherent Framework: Options for FDA Oversight of Genetic Tests, 62 FOOD & 
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B.Evolution of Direct-to-Consumer Genetic Testing 
Direct-to-consumer (“DTC”) genetic testing rapidly expanded as the Human Genome 
Project came to an end.19 Traditionally, genetic tests were only available through healthcare 
providers such as physicians, nurse practitioners, and genetic counselors.20 Healthcare providers 
would meet with the patient, order the appropriate test from a laboratory, collect and send the 
samples, and then interpret the test results with the patient. When the Human Genome Project 
concluded, the field of genetic testing grew and information on gene sequencing was more 
accessible. Then, in 2013, the Supreme Court confirmed that the human genome could not be 
patented in the landmark case of Association for Molecular Pathology v. Myriad Genetics.21  
This decision further enabled competition in the field of genetic testing to expand to an unlimited 
amount of private companies. Thus, these companies began offering genetic tests directly to 
consumers. 
A DTC genetic test is a genetic test that is marketed directly to the consumers through 
print, television, and even the Internet for the variety of health and non-health related reasons, 
without the use of a physician.22 Private companies, such as 23andMe, Navigenics, DeCode and 
Pathway Genomics, offer their genetic testing services at a reasonable price to an individual who 
orders the test via website, receives the test at home, takes a swab of their saliva, sends it back to 
                                                                                                                                                                                  
DRUG L. J. 617, 617 (2007). 
19 Nat’s Human Genome Research Inst., Direct to Consumer Marketing of Genetic Tests (Mar. 23, 2004), 
http://www.genome.gov/12010659; Sarah F. Sunderman, The Need for Regulation of Direct-to-Consumer Genetic 
Testing in the United States: Assessing and Applying the German Policy Model, 12 WASH. U. GLOBAL STUD. L. 
REV. 357, 359 (2013). 
20 Supra note 19. 
21 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 186 L. Ed. 2d 124 (2013). 
22 Sunderman, supra note 19. 
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the laboratory, and then the results are sent directly back to the consumer.23 The consumer never 
has to leave their home and never has to meet with a healthcare provider.  
The advertising of health-related products directly to consumers via television and print 
was formerly only used by pharmaceutical companies, and ultimately created a three billion 
dollar per year pharmaceutical industry.24 By essentially removing the middleman and taking 
advantage of genetic science, the DTC genetic testing industry has used the same tactics and has 
grown to be worth over eight billion dollars.25 For example, in 2002, Myriad Genetics, Inc. 
launched a DTC genetic marketing campaign, which included print and television advertisements 
for BRACAnalysis, a commercial genetic test for the BRCA1 and BRCA2 genes, which have 
been associated with breast and ovarian cancer.26   This campaign resulted in an over three 
hundred percent increase in demand for the genetic test by woman.27 This is only one example of 
success within in the DTC genetic industry and the demand for genetic tests by consumers.  
The FDA, in 2010, estimated that several hundred laboratories offer between 2,500 and 
5,000 different genetic tests directly to consumers.28 Each privately owned company offers its 
own variety of genetic tests that they market to appeal to the average consumer. Some of the 
statements on the leading DTC genetic testing company websites include, “a new look at a 
healthier future,” posted on Navigenics, “take charge of your health and live well at any age,” 
posted on 23andMe, and “let your DNA help you plan for the important things in life,” by 
                                                        
23 Sunderman, supra note 19; Jane Kaye, The Regulation of Direct-to-Consumer Genetic Tests, 17 HU. MOLECULAR 
GENETICS R180, R181 (2008). 
24 Supra note 19.  
25  A.Wesselius, et al., Direct to consumer Genetic Testing, OA Epidemiology (2013), available at 
http://www.oapublishinglondon.com/images/article/pdf/1381968884.pdf. 
26 Jan T. Lowery et al., The Impact of Direct-to- consumer Marketing of Cancer Genetic Testing on Women 
According to Their Genetic Risk, 10 GENET. MED. 888, 888 (2008). 
27  Id. at 890. 
28 Direct-to-Consumer Genetic Testing and the Consequences to the Public Health: Hearing Before the 
Subcomm. on Oversight and Investigations of the H. Comm. on Energy and Commerce, 111th Cong. 7 
(2010). 
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Pathway Genomics.29 This language, along with the price and the promise of life changing 
information, is attractive to any individual with curiosity and a reason the industry has been 
successful thus far. 
C. Types of Genetic Testing Available 
 DTC genetic tests are marketed to consumers for both health and non-health related 
reasons. Some genetic tests meet the definition of a medical device and some will not based on 
how they are marketed and what they are offering to the consumer. Therefore, the classification 
of the type of the genetic information being offered to the consumer is key in future regulation.  
 The non-health related genetic tests offered by companies provide information about a 
person’s ancestry, personality, and even acts as a paternity test. 30  Various companies offer 
genetic tests as a primary means of discovering you own genetic ancestry and other relationship 
based information. For example, 23andMe offers three ancestry options including the Relative 
Finder, which allows the consumer to locate other 23andMe users who match their familial DNA 
profile; the Global Origins test, which locates the historical homes of the consumer’s ancestors; 
and, the Ancestral Lineages test, which promises to track the ancient migrations of the 
consumer’s ancestors.31 This information uses the genetic technology in order to located similar 
DNA within the system. These tests are informational and educational for the consumer. This 
article will focus on genetic tests that are marketed and sold for health related purposes, and 
should be classified as medical devices due to the impact they can have on public health. 
There are three categories of genetic testing available, which are for health related 
                                                        
29 Id.  
30Andrew S. Robertson, Taking Responsibility: Regulations and Protections in Direct-to-Consumer Genetic Testing, 
24 BERKELEY TECH. L.J. 213, 217 (2009). 
31 23andMe, Ancestry, https://www.23andme.com/ancestry (last visited Dec. 7, 2014); Matthew Piehl, Regulating 
Hype and Hope: A Business Ethics Model Approach to Potential Oversight of Direct-to-Consumer Genetic Tests, 16 
MICH. ST. U. J. MED. & L. 59, 63 (2011). 
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purposes. They are pharmacogenetic, predictive, and nutrigenetic tests.32 Pharmacogenetic tests 
provide information about the suitability and effectiveness of a particular drug for the individual 
and predict that individual’s response to particular drug treatments.33
 
Predictive genetic tests are 
marketed as a means of “predicting” an individual potential for developing genetic diseases such 
as breast cancer, diabetes, or cystic fibrosis.34
 
Finally, nutrigenetic tests provide individualized 
nutrition and lifestyle information based on a consumer’s genetic profile in order to assist in 
future healthcare.35
 
For example, if the genetic test determined an individual to be at increased 
risk for developing heart disease, the test results would return diet and lifestyle 
recommendations, such as exercise. All three of these genetic tests offer feedback based on the 
analysis of the genes that can lead to health related decisions on the part of the consumer. These 
decisions can have serious effects on the patient, and, therefore, there must be regulation of the 
companies to ensure the consumers are given accurate and complete information.  
D. Advantages and Disadvantages of Marketing Directly to the Consumer 
Policy makers, scientists, healthcare providers, and individuals have raised significant 
debate on the advantages and disadvantages of DTC testing on not only individuals, but on the 
economy and the genetic science industry. These issues are a direct indication for the need of 
stricter regulation because the threat to public safety is becoming imminent.  
1. Advantages 
1. Empowerment and Autonomy 
 In 2008, TIME magazine declared a DTC genetic testing company, 23andMe’s, retail 
                                                        
32 Pascal Sue, Direct-to-Consumer Genetic testing: A Comprehensive View, 86 YALE J. BIOL MED. 357, 359-360 
(2013). 
33 Rebecca Andar Novick, One Step at a Time: Ethical Barriers to Home Genetic Testing and Why the U.S. Health 
Care System is Not Ready, 11 N.Y.U. J. INT’L L. & POL. 621, 631 (2008). 
34 Id. at 633. 
35 Id.  
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DNA test the “Invention of the Year.”36  This invention received this title, in part, because 
advocates believe it has the potential to make a significant impact on the future of science as well 
as on the future of individuals who use the test. With the ability for a consumer to access their 
own genetic information from home, comes the ability of consumers to have autonomy over their 
own health decisions. Patient autonomy is usually defined as the ability of patients to make their 
own choices about their care, even if their physicians disagree.37 Now, DTC genetic testing has 
moved all of decisions on the consumer without the involvement of a healthcare provider.  As 
the company 23andMe put it, "we believe that your genetic information should be controlled by 
you."38 This autonomy advocates believe allows for consumers to make proactive, preventative, 
and informed lifestyle changes in response to the test results.39   
            Some believe that individuals not only have the right to make their own health decisions, 
but, also, that they have the right to know and have access to their own genetic information.40 
The right to know is an essential right granted to a person and should not be taken away when it 
comes to genetic testing.41 23andMe has argued in their public policy statement, that, 
                                                        
36 Anita Hamilton, Best Inventions of 2008: The Retail DNA Test, TIME (Oct. 29, 2008), 
http://www.time.com/time/specials/packages/article/0,28804,1852747_1854493,00.html. 
37 Novick, supra note 33, at 641. 
38 23andMe, Core Values, http://www.23andme.com/about/values/ (last accessed Dec. 7, 2014). 
39 Karen Norrgard, DTC Genetic Testing for Diabetes, Breast Cancer, Heart Disease and Paternity, 1 NATURE 
EDUC. 1, 1 (2008), available at http://www.nature.com/scitable/topicpage/dtc-gen etic-testing-for-diabetes-breast-
cancer-698 (last visiting December 7, 2014).  
40 Piehl, supra note 31 at 86. 
41 Id.   
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      Genetic information is a fundamental element of a person’s body, identity and 
individuality. As such, the rights that people enjoy with regard to financial, medical 
and other forms of personal information should apply to genetic information as 
well.42 
 
With this enlarged patient autonomy comes a new found sense of empowerment for individuals 
to take control of their own future. According to a study done by the American Marketing 
Association in 2008, more than sixty percent of genetic testing companies use empowerment as 
an emotional appeal to their customers.43 That same study showed that more than 80 percent of 
consumers derived some sort of satisfaction or empowerment from genetic tests.44 It is the belief 
that individuals are empowered to use this information they have a right to make better health 
decisions. This, however, does not take into account the possibility that the information the 
consumer is given is accurate enough to lead to correct decisions.  
       b. Affordability and Accessibility 
Another advantage of DTC genetic testing stems from the ability of companies to offer 
genetic testing in a more accessible and affordable manner across the nation, and even across the 
globe.  Companies offer genetic tests for a reasonable price ranging from $100 to more than 
$2,000, depending on the type of test requested.45 The reason this price can remain low is due, in 
part, to the expansion of science in the genetic field, the unpatentability of the human genome, 
                                                        
42 23andMe, 23andMe Policy Forum: Direct to Consumer Genetic Testing, https://www.23andme.com/about/policy/ 
(last visited Dec. 7, 2014). 
43 Yuping Liu and Yvette Pearson, Direct-to-Consumer Marketing of Predictive Medical Genetic Tests: Assessment 
of Current Practices and Policy Recommendations, 27 JOURNAL OF PUBLIC POLICY & MARKETING 131,142 (2008). 
44 Id.  
45 NAT'L INSTS. OF HEALTH, Handbook: Help Me Understand Genetics, Genetics Home Reference (2014), available 
at http://ghr.nlm.nih.gov/handbook.pdf.   
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and the widespread utilization of genetic sequencing.46  
As genetic tests become more affordable, they become more accessible to larger amounts of 
people. No longer is an individual’s geographic location or ability to meet with a physician 
relevant. Consumers now have a testing kit mailed to them by ordering online, no matter where 
they are geographically located.47 And with a lower price, more consumers are able to afford the 
testing, thus, reaching more consumers geographically and economically. Consequently, putting 
more consumers health safety at risk.  
c. Privacy 
Another positive aspect raised by proponents of DTC genetic tests is the increase in privacy 
that comes from not having to need a prescription or involve a healthcare practitioner. During the 
Human Genome Project, concerns were raised that an individual’s genetic test results may be 
used by insurance companies, employers, or the government against the individual.48 In 1995, 
former President Bill Clinton issued an executive order prohibiting the federal government from 
using personal genetic information for employment purposes. 49  Following, in 2008, former 
President George W. Bush signed the Genetic Information Nondiscrimination Act, GINA, which 
provides for enhanced federal protection of genetic information and includes prohibitions on the 
use of genetic information by private employers in making employment decisions and health 
insurance companies in making decisions to raise individual premiums or deny benefits.50 DTC 
genetic tests do not require the involvement of healthcare providers and therefore the results will 
                                                        
46 Piehl, supra note 31, at 62. 
47 Norrgard, supra note 39. 
48 Novick, supra note 33. 
49 National Human Genome Research Institute, Genetic Discrimination Fact Sheet, 
http://www.genome.gov/10002328 (last visited Dec. 7, 2014). 
50 National Human Genome Research Institute, Genetic Information Nondiscrimination Act of 2008, The Genetic 
Information Nondiscrimination Act of 2008 (GINA), PUB. L. NO. 110-233, 122 Stat. 881 (2008). 
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never be documented in an individual’s medical record, unless the consumers wanted to share 
the information. Without publicizing the results, the genetic information cannot effect 
employment or insurance and thus avoids the entire issue of GINA.51 The privacy advantage 
stems down to the fact that unless you want to share the results, the results will remain within 
your home where you ordered and received them. This makes the tests more appealable to 
consumers because they alone can know their genetic predispositions or health status, and take 
the necessary steps, without fear of discrimination of some kind. 
2. Disadvantages 
a. Lack of Genetic Counseling  
The majority of the drawbacks associated with DTC genetic testing stem from the 
absence of a medical professional. When a patient physically visits a doctor to retrieve a genetic 
test, they are more likely, if not definitely, going to receive advice and counseling regarding the 
pretest expectations and the post test results. DTC genetic testing is offered in the absence of a 
prescription from a healthcare provider and absent counseling on possible courses of actions, 
both before and after the genetic test in administered, which can leave a consumer uneducated 
and at risk.  
Some companies do offer counseling. According to a study conducted by the Genetic and 
Public Policy Center, as of August 2011, there were twenty DTC genetic testing companies in 
the United States and seven additional DTC genetic testing companies that required physicians to 
request the DNA tests.52  Of the twenty DTC genetic testing companies, eight offered some sort 
of genetic counseling to consumers, though only five did so without additional costs to the 
                                                        
51 Bridget M. Kuehn, Risks and Benefits of Direct-to-Consumer Genetic Testing Remain Unclear, 300 J. AM. MED. 
ASS’N 1503, 1504 (2008). 
52 Sunderman, supra note 19, at 360. 
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consumer.53 The counseling offered is also not mandatory and not pushed by the companies. 
Some companies also only offered counseling after the consumer already purchased the test.54 
This removes the ability for the consumer to be advised on expectations when beginning the test.  
Absent counseling to review the results, consumers can easily misinterpret their results. 
This opens them up to make adverse medical decisions, thus eliminating the entire point of the 
test to help in health decisions. 55  For example, an individual may undergo unnecessary 
procedures such as a mastectomy in response to a genetic test evidencing an increased risk of 
breast cancer. The consumer might also cease using prescribed medications without speaking to 
their healthcare professional first. Without the proper counseling from a health care provider or 
counselor, consumers cannot use the results to their full potential, and the results may even leave 
the consumer in a worse health state.  
b. Informed Consent 
On top of the lack of genetic counseling, there is more than a possibility of a lack of 
informed consent that worries many medical professionals and policy makers. Informed consent 
is a fundamental principle in health law and allows for a doctor to discuss the risks and benefits 
with a patient, allows the patient to ask questions, disclose possible alternatives and ultimately 
allow the patient to come to the most informed and safe decision.56 Due to a lack of genetic 
counseling, there is no way to ensure that the consumer is aware of all of these essential elements 
and even consents to them. The consumer is as informed as the company want them to be and 
does not have anyone to ask questions and discuss which route to take.  
                                                        
53 Id. 
54 Jill Goldman et al., Genetic Counseling and Testing for Alzheimer Disease: Joint Practice Guidelines of the 
American College of Medical Genetics and the National Society of Genetic Counselors, 13 GENETICS IN 
MEDICINE 597, 602 (2011). 
55 Sivan Tamir, Direct-to-Consumer Genetic Testing: Ethical- Legal Perspectives and Practical Considerations, 18 
MED. L. REV 213, 219 (2010). 
56 Zulfiqar A. Bhutta, Beyond Informed Consent, 82 BULL. WORLD HEALTH ORG. 771, 774 (2004), available 
at http:// www.who.int/bulletin/volumes/82/10/771.pdf. 
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       There is another informed consent issue relating to the use of the results in scientific 
research. There is a concern that “there is a release of the genetic test results or genetic materials 
to third parties to whom the individual never intended to impart the information or material.” 57 It 
is a fact that some genetic testing services that are marketing to consumers directly online, sell 
their customers information to research institutions, without the consent of the consumer.58 Some 
companies inform consumers that their genetic information may be sold to third parties and used 
for research purposes. 59 They even give the consumers the option to consent to research by 
simply checking a box. This unapproved sharing or selling of information raises privacy and 
confidentiality issues for the consumer, as well as property right issues that could have serious 
implications.60 If the consumer does consent, there is an issue as to whether the individual fully 
understand the ramifications of consenting to the sharing of their genetic information for 
research purposes. 61 
        This next informed consent issue is raised because DTC genetic testing companies have no 
definitive way of knowing if the individual requesting the test is actually sending in their own 
DNA sample.62 For example, an individual could collect the genetic material of another person 
without that person’s consent and subsequently obtain and use the genetic information received 
from the DTC genetic testing company. Some companies even market to give the DNA test 
results as the “perfect gift.” This is a violation of informed consent, as well as privacy, that 
bypass the entire informed consent principle which is a major component of the everyday 
healthcare system, and for good reason.  
                                                        
57 Gabrielle Kohlmeier, The Risky Business of Lifestyle Genetic 
Testing: Protecting Against Harmful Disclosure of Genetic Information, 2 UCLA J. L. & TECH. 11, 5 (2007). 
58 Id. at 27. 
59 Kohlmeier, supra note 57, at 26. 
60 Id.   
61 Id. at 27.  
62 Tamir, supra note 55.  
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c. Accuracy  
Scientific accuracy concerns are at the forefront of the negatives. As genetic science is still 
being developed and new genetic disorders are discovered every day, the complete accuracy of 
the results cannot be fully reached.63  In fact, different companies have come to different results 
based on the varying information they use in calculating risks and due to the incompletion of 
identifying every genetic disorder. 64  For example, one study comparing 23andMe and 
Navigenics test results found that only two-thirds of relative risk predictions between the two 
companies qualitatively matched.65  
In addition to undeveloped science, there are additional factors that contribute to the future 
of a person’s health and those factors are not being calculated into the test results.66  Factors such 
as the environment, your daily lifestyle, and even your personality can have an effect on your 
health.67 For example, a smoker will clearly be more prone to lung cancer than a nonsmoker or 
different nationalities are more prone to specific diseases. The consumer receives the results 
based on their DNA alone, and does not take into account these other factors that will contribute 
to their future and present health. Thus, not only are the results not consistent, they are not 
considering outside factors, which can contribute to the accuracy of the test results and put 
patient safety at risk.  
d. Emotional Harm 
                                                        
63  Supra note 32, at 359. 
64 Pauline C. Ng et al., An Agenda for Personalized Medicine, 461 NATURE 724, 724 (2009), available at 
http://www.gis.a-star.edu.sg/internet/site/data/sup_data/2249/an_agenda_for_perso 
nalized_medicine.pdf. 
65 Id.  
66 Id. 
67 Muin J. Khoury et al., Do We Need Genomic Research for the Prevention of Common Diseases with 
Environmental Causes?, 161 AM. J. EPIDEMIOLOGY 799, 800 (2005). 
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 Finally, there is physiological and emotional harm that consumers face after purchasing 
these genetic tests. Since consumers will not receive meaningful genetic counseling and, 
consequently, may misinterpret their results, there are psychological reactions based upon a 
flawed understanding of these test results.68
 
Misinterpretation of results can lead to a false sense 
of security if results show a lower probability of disease than anticipated.69 The opposite may 
also happen, and a consumer may interpret a test result as indicative of death, which could lead 
to ′′severe psychological trauma and possibly suicide.”70  Healthcare providers also fear that 
consumers, based on the results of these tests, will seek out additional unnecessary procedures or 
treatment, which will weigh heavily on the healthcare system as a whole.71  Clearly, DTC genetic 
tests are generating confusion, anxiety and even false reassurance. 
            Misleading advertising by DTC genetic testing companies minimizes the risks and 
overstates the possible benefits of genomic testing. The advertisements may “induce vulnerable 
consumers to purchase the tests, thereby diminishing their autonomy.” 72  Marketing and 
advertising tends to appeal to the consumer, while posing risks without them even knowing. 
Therefore, the potential for results to be misinterpreted or misused, and yet may not even be 
accurate, leads to serious health concerns that must be clearly regulated in the hope of 
compliance to protect public safety and well being.  
III. THE CURRENT REGULATORY FRAMEWORK 
                                                        
68 Stuart Hogarth et al., The Current Landscape for Direct-to-Consumer Genetic Testing: Legal, Ethical, and Policy 
Issues, 9 ANN. REV. OF HUMAN GENETICS 161, 168 (2008). 
69 Id. 
70 Kohlmeier, supra note 57, at 6.  
71 Lauren B. Solberg, Over the Counter but Under the Radar: Direct-to-Consumer Genetic Tests and FDA 
Regulation of Medical Devices, 11 VAND. J. ENT. & TECH. L. 711, 721 (2009). 
72 Deepthy Kishore, Comment: Test at Your Own Risk: Your Genetic Report Card and the Direct-to-Consumer Duty 
To Secure Informed Consent, 59 EMORY L.J. 1553, 1553-54 (2010); Supra note 19, at 360.  
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 Given the serious health and safety concerns driven by DTC genetic tests, the current 
regulatory landscape for these tests is inadequate. Genetic testing ′′falls between several 
regulatory cracks within the federal government′′ numerous government entities 
oversee genetic testing, but together no entity covers all genetic tests.73 Figure 1 demonstrates 
the current regulatory framework of the FDA and CMS, which both have some authority over 
genetic tests. Together, they can create regulations to close the gaps and cover all genetic tests.  
 
 
 
Figure 1: Current Regulatory Framework of CMS and FDA 
 
 
                                                        
73Gail H. Javitt, et al., Direct-to-Consumer Genetic Tests, Government Oversight, and the First Amendment: What 
the Government Can (and Can’t) Do to Protect the Public’s Health, 57 OKLA. L. REV. 251, 258 (2004). 
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A. Clinical Laboratory Regulation by CMS 
 The Centers for Medicare and Medicaid Services has primary authority for 
regulating laboratory testing under the Clinical Laboratory Improvement Amendments of 1988, 
or CLIA.74 CLIA regulations are designed to ensure the analytical validity of genetic testing by 
covering how the tests are performed and the quality of the procedures and laboratory 
personnel.75 CLIA does not address clinical validity, utility, or review laboratory marketing 
communications.76 
 A laboratory is defined under CLIA as, 
a facility for the biological, microbiological, serological, chemical, immune-
hematological, hematological, biophysical, cytological, pathological, or other 
examination of materials derived from the human body for the purpose of providing 
information for the diagnosis, prevention, or treatment of any disease or impairment of, 
or the assessment of the health of, human beings.77 
 
In short, CLIA covers all laboratories that conduct testing on human specimens to “diagnose, 
prevent, or treat any disease.”78 The amendments prohibit laboratories from performing clinical 
laboratory tests without being issued a federal certificate.79  CMS currently regulates laboratory-
testing activities of over more than 200,000 laboratory entities within the United States.80 DTC 
genetic testing companies use laboratories that collect “materials derived from the human body” 
of its consumers ′′for the purpose of providing information for the diagnosis, prevention, or 
treatment,” and therefore fall into the purview of CLIA regulated laboratories.   
                                                        
74 42 U.S.C. § 263a-q. 
75 42 C.F.R. § 493.1253(b). 
76 Neil A. Holtzman, FDA and the Regulation of Genetic Tests, 41 JURIMETRICS 53, 57 (2000). 
77 42 C.F.R. § 493.2. 
78 42 U.S.C. § 263a; U.S. Dep't of Health and Human Servs., Ctrs. for Medicare & Medicaid Servs., Clinical 
Laboratory Improvement Amendments (CLIA): Overview, http://www.cms.hhs.gov/clia/ (last visited Dec. 7, 2014).  
79 42 U.S.C. § 263a. 
80 42 U.S.C. § 263a(a). 
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 Once a lab is covered by CLIA, it is then categorized as waived, moderate complexity, or 
high complexity.81 This classification determines the level of control by CMS. Waived tests are 
those “so simple and accurate as to render the likelihood of erroneous results negligible” or those 
which "pose no reasonable risk of harm to the patient if the test is performed incorrectly.” 82 The 
remaining are placed as moderate or high based on a set of criteria, including the difficulty of the 
scientific and technical knowledge necessary to conduct the test, the stability and reliability of 
the materials used, and the level of judgment required by those administering the tests. Genetic 
tests qualify as “high complexity,” due to the high level of skill needed according to the factors.  
 Although classified as a high complexity test, genetic testing is not subject to all 
of the requirements required of other moderate and high complexity tests. Moderate and high 
complexity tests must follow quality assurance programs and undergo proficiency testing.83  The 
proficiency testing assures the accuracy of the test and imposes requirements specific to that 
specialty. 84   However, under CLIA, “there are no specified quality control, personnel, or 
proficiency testing requirements mandated ... for most genetic tests.”85 As there are no specific 
proficiency standards to which a genetic testing lab must adhere, there is no requirement for 
genetic tests to meet specific standards for accuracy, reliability, or clinical validity. Instead the 
lab is only required to “establish and maintain the accuracy of its testing procedures.” 86 
 In 2000, the Clinical Laboratory Improvement Advisory Committee (“CLIAC”) 
published a Notice of Intent, proposing amendments to CLIA that would create a specific genetic 
                                                        
81 42 C.F.R. § 493.15. 
82 42 C.F.R. § 493.5. 
83 42 C.F.R. § 493.17. 
84 Id.  
85 Am. Soc’y of Human Genetics Bd. of Dirs., ASHG Statement on Direct-to-Consumer Genetic Testing in the 
United States, 81 AM. J. HUMAN GENETICS 635, 636 (2007), available at 
http://www.dnapolicy.org/resources/ASHGDTC statement.pdf. 
86 42 C.F.R. §493.801(a)(2)(ii). 
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testing section in the regulations. 87  However, CLIA was never amended according to this 
suggestion. Therefore, it remains that CLIA is only governing the conduct of the laboratory, not 
the accuracy of the result obtained by the genetic tests created in CLIA certified laboratories.   
B. Medical Device Regulation by the Food and Drug Administration 
 The FDA, under the Federal Food Drug & Cosmetic Act (“FDCA”) has the authority to 
regulate medical devices, and plays the largest role in the oversight of genetic tests.88 The FDA is 
tasked with protecting the public’s health by assuring the ′′safety, effectiveness, and security” of 
medical inventions.89 According to the Supreme Court, “viewing the FDCA as a whole, it is 
evident that one of the Act’s core objectives is to ensure that any product regulated by the FDA 
is safe and effective for its intended use.” 90 Consequently, whether the FDA regulates a device is 
determined by how it comes to the market and what its intended use is.  
1. Classification of Medical Devices 
 A medical device is defined in the FDCA as “an instrument, apparatus, implement, 
machine, contrivance, implant, in vitro reagent, or other similar or related article, including any 
component, part, or accessory, which is . . . intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of disease...” 91  This broad 
definition, simply put includes equipment, reagents, and other components used by laboratories 
to analyze human specimens for the “cure, mitigation, treatment, or prevention of disease.”92 
Thus, genetic tests would be included because their intended use is in the cure, treatment, or 
prevention of disease.  
                                                        
87 U.S. Dep't of Health and Human Servs., Notice of Intent; Genetic Testing Under the Clinical Laboratory 
Improvement Amendments, 65 FR 25928-02 (2000). 
88 21 U.S.C § 321(h). 
89 21 C.F.R. §808.1; FDA, FDA Fundamentals, 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm (last visited Dec. 7, 2014). 
90 Food & Drug Admin. v. Brown & Williamson Tobacco Corp., 120 S. Ct. 1291, 146 L. Ed. 2d 121 (2000). 
91 21 U.S.C.A. § 321(h). 
92 21 U.S.C.A. § 321(h)(2). 
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 The FDA then classifies medical devices into three categories based on the level of risk 
posed to the consumer.93  The FDA, like CMS, uses these categories to determine how much 
control is needed to ensure the safety and effectiveness of each device. Class I devices are 
subject to the least FDA regulation and may be introduced directly into United States commerce. 
This is because they do not present an “unreasonable risk of illness or injury.”94 As Class I 
devices pose minimal potential for harm, they are only subject to FDA “General Controls” 
including registration, labeling, and good manufacturing.95 Class II devices have an increased 
safety risk and are subject to greater FDA controls to ensure safety and effectiveness.96 Class II 
devices are subject to the “General Controls”, as well as “Special Controls,” which include 
stricter labeling requirements, performance standards, and post market surveillance. 97  Most 
importantly, Class II devices must submit a premarket notification, or 510(k), before being 
marketed.98 Finally, Class III devices are defined as those, which are “supporting, sustaining, or 
preventing impairment of human health,” or those that present a potential “unreasonable risk of 
illness of injury.” 99  The FDA believes that general controls and special control would not 
provide adequate reasonable assurance of the safety and effectiveness, and instead requires a 
stricter pre market approval, PMA, before being marketed.100 Most genetic tests, if found to be a 
medical device, will be found to be Class II or Class III.  
2. Premarket Processes  
                                                        
93 21 U.S.C.A.§ 360c(a)(1). 
94 21 U.S.C.A. § 360c(a)(1)(A). 
95 21 C.F.R § 801 (2013). 
96 21 U.S.C.A. § 360c(a)(1)(B). 
97 21 U.S.C.A. § 360c(a)(1)(B). 
98 21 U.S.C.A. § 360(a)(B)(ii). 
99 21 U.S.C.A. § 360c(a)(1)(C). 
100 21 C.F.R. §814.1; U.S. Food and Drug Administration, Premarket Approval (Medical Devices), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevi 
ce/PremarketSubmissions/PremarketApprovalPMA/default.htm (last visited Dec. 7, 2014). 
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 Medical device classification will dictate the level of control by the FDA and the level of 
engagement necessary by companies to be able to comply with the regulations and legally be 
able to market and sell their devices. Most Class II and some Class III devices must submit a 
premarket notification, or 510(k), to the FDA before marketing. 101 This notification requires 
manufactures to demonstrate that their medical device is “substantially equivalent” to a medical 
device currently on the market.102 A device is “substantially similar” if it has the same intended 
use and uses the same technology as another legally marketed device.103 A successful 501(k) 
submission will result in the FDA clearing the device for sale.  
 Most Class III devices must go through the rigorous PMA process.  In this process, 
companies must demonstrate that their device is safe and clinically valid through “adequate and 
well-controlled” clinical trials involving human subjects.104 Once the company shows adequate 
scientific evidence proving the device is safe and effective for its intended use, the FDA will 
approve the new device to be distributed.  
3. Classification of Genetic Tests 
 The definition of a medical device suggests that any type of genetic test, whether it is 
marketed directly to the consumer or not, is a medical device because it is used “to diagnose or 
prevent a disease.”105 However, the FDA bas further classified genetic tests and used varying 
regulations for each classification.  
 The FDA expanded the definition of medical device in 1976 to include in vitro diagnostic 
devices. In vitro diagnostic devices (“IVDs”) are those “reagents, instruments, and systems 
intended for use in the diagnosis of disease or other conditions, including a determination of the 
                                                        
101 21 C.F.R. § 807. 
102 21 C.F.R. § 807.92. 
103 21 C.F.R. § 807.92(a)(3).  
104 21 C.F.R. § 314.126. 
105 21 U.S.C. § 321(h)(2). 
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state of health, in order to cure, mitigate, treat, or prevent disease or conditions arising from a 
disease.” 106 The FDA only regulates genetic tests as IVDs “if the components of the test are 
bundled together, labeled for a particular use, and sold to an outside laboratory as a unit”, or “test 
kit.”107 The FDA classifies tests that fit this definition as Class II or Class III devices, subjecting 
them to 510(k) or PMA approval processes. Of the hundreds of genetic tests currently available 
only a handful are sold as test kits. In fact, IVDs subject to FDA review make up only about one 
percent of the commercially available genetic tests.108  
 The majority of genetic tests available today are classified as laboratory-developed tests, 
also called “home brews.” The FDA defines laboratory-developed tests ("LDTs") as “in vitro 
diagnostic devices intended for clinical use and designed, manufactured and used within a single 
laboratory.”109  They are developed in house by laboratories and do not become part of the test 
kit, but instead are marketed as proprietary tests. Historically, the FDA has not enforced 
regulatory provisions with respect to LDTs, but only exercised “enforcement discretion.” This 
was because the FDA believed that LDTs were generally “relatively simple, well-understood, 
low risk tests that diagnosed rare diseases and conditions, and that were intended to be used by 
physicians and pathologists in a single institution where they were actively involved in patient 
                                                        
106 21 C.F.R. § 809.3(a). 
107 Audrey Huang, FDA Regulation of Genetic Tests, GENETICS & PUB. POLICY CTR., 
http://www.dnapolicy.org/images/issuebriefpdfs/FDA_Regulation_of_Genetic_Test_Issue_Brief.pdf (last updated 
May 30, 2008). 
108 Jennifer A. Gniady, Regulating Direct-to-Consumer Genetic Testing: Protecting the Consumer Without 
Quashing A Medical Revolution, 76 FORDHAM L. REV. 2429, 2438 (2008). 
109 FDA, Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: FDA 
Notification and Medical Device Reporting for Laboratory Developed Tests (LDTS)(Oct. 3, 2014), available at 
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.
pdf. (hereinafter FDA Guidance)  
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care.”110 Thus a majority of genetic tests that are classified as LDTs were able to enter the market 
without undergoing any FDA premarket evaluation for safety, effectiveness, or accuracy. 
 However, due to technological and scientific advances, LDTS has become more complex. 
The FDA has determined that heightened review of LDTs is necessary to mitigate risks to 
patients because of high risk they pose to consumers. In 2010, the FDA stated that it had 
reconsidered its position regarding non-enforcement of LDTs, reasoning that the industry was 
shifting toward using component parts that were not individually regulated and were being used 
to assess high-risk diseases and direct treatments.111 In September of 2014, the FDA issued two 
Draft Guidance documents, which set out a regulatory framework, similar to that of other 
medical devices, for regulating LDTs going forward.   
 As seen in Figure 2, the classifications of genetic tests all intersect. DTC genetic tests can 
be both test kits and LDTs. The issue arises because DTC genetic testing companies outsource to 
third parties, and therefore, the genetic tests are falling into the regulatory gaps. In the end, they 
are all genetic tests, but where they are manufactured, the intended use of each test, and what 
they are marked for plays a role in the level of regulation by the FDA.   
 
 
                                                        
110 Oversight of Laboratory Developed Tests; Public Meeting; Request for Comments, 75 FED. REG. 34, 464 (June 
17, 2010). 
111 Id.  
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Figure 2: Types of Genetic Tests 
IV. FDA ENFORCEMENT ACTION 
A. Warning Letters 
 Marketing and distributing a medical device not cleared or approved by the FDA is a 
violation of the FDCA. 112 Warning Letters are issued in reaction by the FDA to put the company 
on notice of the violation that may lead to further enforcement action if not promptly and 
adequately corrected.113 The DTC genetic testing industry caught the attention of the FDA in 
2010, when Pathway Genomics announced that it was going to partner with Walgreens and sell 
its genetic test in drug stores across the country. 114 The FDA responded by sending Warning 
Letters to twenty three genetic testing companies for violations of the medical device regulation 
                                                        
112 21 U.S.C § 331(a). 
113 Howard Dorfman, Pharmaceutical Compliance & Enforcement Answer Book 2014, 69-70 (Practising Law 
Institute). 
114  Robert Stein, Company Plans to Sell Genetic Testing Kit at Drugstores, WASH. POST (May 11, 2010), 
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under FDCA. This resulted in a majority of the companies dropping out of the DTC genetic 
testing market and discontinuing the sale of their health related genetic tests. 
 One company, 23andme has caught the attention of the media because they tried to 
comply with the FDA regulations. More than 800,000 Americans have used their at home 
genetic tests, which, when used for a health related report, can provide information on over 254 
diseases and conditions.115 23andMe received one of the Warning Letters from the FDA accusing 
them of marking medical devices without clearance.  
 The FDA in its Warning letter to 23andMe demanded them to stop marketing its “Saliva 
Collection Kit and Personal Genome Service (“PGS”).”116 The FDA was clear that they believed 
their product was an unapproved and uncleared device under the FDCA because of the intended 
uses cited on the website. 23andme marketed on its website health reports that provided for ′′a 
first step in prevention′′ and enabling users to ′′take steps toward mitigating serious diseases.”117  
The FDA in its letter wrote, “some of the uses for which PGS is intended are particularly 
concerning, such as assessments for BRCA-related genetic risk and drug responses because of 
the potential health consequences that could result from false positive or false negative 
assessments for high-risk indications such as these.”118  The FDA reasoned that most of the 
intended uses were health related and had not been classified, and, thus, require premarket 
approval before being distributed. 119 This means they deemed their product a Class III medical 
device due to the high risk they posed to consumers.  
                                                        
115 23andMe, Fact Sheet, http://mediacenter.23andme.com/fact-sheet/ (last visited Dec. 7, 2014). 
116 Letter from Alberto Gutierrez, Dir., Office of In Vitro Diagnostics and Radiological Health, Ctr. for Devices & 
Radiological Health, Food & Drug Admin., U.S. Dep't of Health & Human Services, to Anne Wojcicki, 
C.E.O., 23andMe, Inc. (Nov. 22, 2013), available 
at http://www.fda.gov/iceci/enforcementactions/warningletters/2013/ucm376296.htm (hereinafter Letter from 
Alberto Gutierrez). 
117 Id.  
118 Id.  
119 Id.  
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 In a press statement, 23andMe stated that “we recognize that we have not met the FDA’s 
expectations…. our relationship with the FDA is extremely important to us and we are 
committed to fully engaging with them to address their concerns.” 120 Promptly after, 23andme 
began the 501(k) clearance process on a few of its nearly two hundred genetic tests. But they 
never began the PMA process. Ultimately, 23andme failed to satisfy the FDA requirements as to 
the validity of their genetic tests under the 501(k) process. The FDA shut them down in 
November 2013 with regards to their health related genetic tests in order to protect patient safety.        
The company is still permitted to sell the DNA analysis kit in the United States, but it can no 
longer provide health reports based on a persons individualized genetics. The 23andme current 
website now states at the top of the page, “23andMe provides ancestry-related genetic reports 
and uninterrupted raw genetic data. We no longer offer out health-related genetic reports.”121 
Current 23andMe customers who received health-related results prior to November 2013 will 
continue to have access to health related information. However, no new health-related updates 
will be provided. The FDA has stated that even after many interactions with 23andMe, “we still 
do not have any assurance that the firm has analytically or clinically validated the PGS for its 
intended uses, which have expanded from the uses that the firm identified in its submissions.”122 
The 501(k) submission was the start of the 23meandMe attempting to get its health related 
genetic tests back on the market.  
B. Enforcement Discretion Revised 
 Historically, the FDA was exercising enforcement discretion on whether or not to enforce 
FDCA regulations when it came to LDTs. Enforcement discretion means that the agency retains 
                                                        
120 23andMe, Statement Regarding FDA Warning Letter, http://blog.23andme.com/news/23andme-statement-
regarding-fda-warning-letter/ (last visited Dec. 7, 2014). 
121 23andMe,Welcome, https://www.23andme.com (last visited Dec. 7, 2014). 
122 Letter from Alberto Gutierrez, supra note 116. 
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the option to take enforcement action if safety concerns are identified, on a case-by-case basis. In 
Heckler v Chaney, the court noted “refusals of administrative agencies to exercise enforcement 
authority involve a complicated balancing of factors, which are not suitable for judicial review.” 
123 Thus, they are presumptively "committed to agency discretion by law," which means the FDA 
does not have to actively enforce its regulatory requirements, but reserves the right to do so in 
the future or in particular instances.124  Today, as mentioned early, due enhanced public safety 
concerns regarding LDT testing, the FDA has issued two draft guidance documents in regards to 
regulation going forward. Although these long awaited guidance documents are nonbinding, 
courts generally give deference to them and they lay out what the FDA is concerned with. 
            In the Framework Guidance, the FDA explains its intention to regulate LDTs not by 
enforcement discretion, but using a risk based approach. Over the course of the next ten years or 
so, the FDA will phase in regulation based on the level of risk posed.125 The new regulation will 
utilize the current three-class system used for medical device regulation. 126  
             For moderate and high risk LDT’s, the FDA intends to enforce applicable regulatory 
requirements, including registration and listing, adverse event reporting, premarket review, and 
quality system requirements. 127  High-risk LDTs will be required to begin making PMA 
submissions within a year after the guidance is finalized, and moderate-risk LDTs will be 
required to begin making 501(k) submissions beginning the fifth year after the guidance is 
finalized.128 The FDA also makes it clear that it plans to continue enforcement discretion for 
                                                        
123 Heckler v. Chaney, 470 U.S. 821, 105 S.Ct. 1649 (1985). 
124 Id. at 833. 
125 FDA Guidance, supra note 109.  
126 Id.; Ben Berg et al., Regulatory Overview of Proposed LDT Framework, NSF Health Sciences (2014), available 
at http://www.nsf.org/newsroom_pdf/md_reg_overview_proposed_ldt_framework.pdf. 
127 FDA Guidance, supra note 109. 
128 Id.  
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LDTs used solely for forensic purposes and LDTs used in CLIA-certified high-complexity 
histocompatibility laboratories for transplantation, as well as low risk LDTs. 129 
            The guidance documents provide insight into what the FDA is thinking in regards to the 
industry. The guidance is intended to prove an oversight framework that will assure that devices 
within the definition of LDTS will comply with the appropriate levels of regulatory controls to 
assure that they are safe and effective. Footnote 4 of the LDT Guidance states, “FDA generally 
does not exercise enforcement discretion for DTC genetic tests regardless of whether they meet 
the definition of an LDT. Therefore, the enforcement policies in this guidance do not apply to 
DTC genetic tests, and FDA’s usual enforcement policies apply to DTC genetic tests.”130 The 
addition of this sentence is another validation that the FDA plans to provide direct guidance for 
the industry, and potentially knows they have to.   
C. Government Accountability Office Report  
 The Government Accountability Office (“GOA”) is a federal agency tasked with 
improving the performance and to ensure the accountability of the federal government for the 
benefit of the American people.131 The GAO first investigates the legitimacy of DTC genetic 
tests in 2006. 132 The GAO purchased nutrigenetic tests from four unnamed DTC genetic test 
companies and posed as twelve individual consumers by sending in DNA samples. 133  The 
results proved to be generic and ambiguous, according to the report, which states that, “these 
results were so ambiguous as to be meaningless and could apply to any human who submitted 
                                                        
129 Id.   
130 FDA Guidance, supra note 109. 
131 U.S. Government Accountability Office, About GAO, http://www.gao.gov/about/index.html (last visited Dec. 7, 
2014). 
132 U.S. Gov’t Accountability Office, GAO-06-977T, Nutrigenic Testing: Tests Purchased from Four Web Sites 
Misled Consumers, Testimony Before the S. Special Comm. on Aging (July 27, 2006), available at 
http://www.gao.gov/new. items/d06977t.pdf [hereinafter GAO - 2006]. 
133 Id. 
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DNA.”134 It concluded that the companies provided results that were so vague as to be virtually 
useless.135 
 Then again in 2010, the GAO issued another report demonstrating the issues with DTC 
genetic tests at a House Committee Hearing on the regulation of genetic tests.136 This time, the 
GAO purchased ten tests from four different companies and then selected five donors and sent 
two DNA samples from each donor to each company, with one using factual information about 
the donor and one using fictitious information, such as incorrect age and race or ethnicity.137 The 
goal was to investigate the marketing practice, testing data, and customer support.138 Throughout 
the investigation, the GAO made undercover calls seeking health advice and inquiring on privacy 
and test reliability. 
 The GAO received similar results to the to the 2006 study. In its report, the GOA 
concluded that the services were misleading, deceptive, fraudulent, and nearly useless. 139 For 
example, GAO’s donors often received risk predictions that varied across the four companies and 
received DNA based predictions that conflicted with their actual medical conditions.140 Further, 
the companies failed to provide any expert advice as was promised. 141  Gregory Kutz, the 
Managing Director of Forensic Audits and Special Investigations for the GAO, testified before 
the Senate Special Committee on Aging that the sampled genetic tests at best provided little or 
no value to consumers, and at worst “could frighten a consumer into thinking that they will 
                                                        
134 Id.  
135 Id.  
136 U.S. Gov’t Accountability Office, GAO-10-847T, Direct-to-Consumer Genetic Tests: Misleading Test Results 
are Further Complicated by Deceptive Marketing and Other Questionable Practices 1-2 (2010), available at 
http://www.gao.gov/new.items/d10847t.pdf. 
137 Id.  
138 Id.  
139 Id. 
140 Id. 
141 Id.  
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develop cancer, osteoporosis, heart disease, or brain aging.” 142  After informing the FDA, 
National Institutes of Health, and Federal Trade Commission (“FTC”) of the results, the GAO 
referred all of the companies investigated to the FDA and FTC for appropriate action related to 
their claims. This report by the GAO is a further demonstration of the potential harms that can be 
caused by the DTC genetic testing industry, as well as validates the need for regulation.  
D. Secretary Advisory Committee 
 The Secretary’s Advisory Committee for Genetics Health and Society (SACGHS) is a 
public forum for deliberation on policy issues raised by the development and use of genetic tests 
and, as warranted, to provide advice on these issues.143  In 2001, the SACGHS determined that 
the current oversight of genetic tests was insufficient to ensure safety, accuracy, and validity.144 
Then, in 2008 and in 2010, it was tasked with “investigating specific questions related to the 
adequacy and transparency of the current oversight system for genetic testing.”145 
In the most recent 2010 report, the SACGHS identified gaps such as: (1) federal oversight of 
DTC testing, specifically the lack of review by FDA and FTC of genetic-testing claims and 
promotional materials made by DTC genetic-testing companies; (2) the evidence of clinical 
validity and utility for most DTC genetic tests; (3) privacy and research protections for 
consumers using DTC genetic services given the potentially limited applicability of federal laws 
and inadequacy of state law protections; and (4) inadequate knowledge of DTC testing by 
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healthcare providers who are asked about their patients.146  The Committee then provided a 
number of action-guiding recommendations, the most important being that the FDA and CMS 
“should develop the necessary guidance and/or regulations that close gaps in the oversight′′ of 
DTC genetic testing.” 147  In addition, in both the 2010 and 2008 approach, SACGHS 
recommended the use of a risk-based approach by the FDA.  
V. RECOMMENDATIONS FOR THE FDA’S FUTURE ROLE IN DIRECT-TO-CONSUMER GENETIC 
TESTING REGULATION 
A. Issue Clear Regulations for the Industry 
 The DTC genetic testing industry is in disarray. The negatives of marketing health related 
genetic tests directly to the consumer outweigh the positives, with patient safety at the forefront 
of the risks.  This increased risk to the patient to make a rash decision affecting their health, such 
as stopping a medication or drastically changing their diet, without ever speaking with a 
healthcare professional, not only poses a risk to that patient, but to the future healthcare system 
in its entirety. The FDA, the GAO, and other agencies and policymakers have recognized the 
magnitude of the risk posed by the DTC genetic testing industry. These issues have been around 
since the earlier part of the decade yet has remained unresolved. Although the FDA has taken 
some action to stop DTC genetic testing companies from marketing their products, they have not 
given the companies the chance to comply.  
 Federal regulation of genetic tests is not clearly defined. The inadequacy of regulation 
has resulted in no oversight or enforcement as to ensure the validity and accuracy of the 
information provided to the consumers through the results of genetic tests. In the absence of clear 
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regulations, companies that offer DTC genetic tests are left astray and unsure about what they 
can do to comply.  The companies who market and sell DTC genetic tests do not know how to 
comply and cannot complete their mission of sharing genetic information with individuals and 
spreading the evolution of science and personalized medicine. 
 The FDA is the agency with the best legal authority and resources to ensure the safety 
and efficacy of DTC genetic tests.148 The FDA already has pushed for stricter regulation of LDTs 
and IVDs, but when the FDA will decide to act precisely in regards to DTC genetic testing is 
unclear.  We know they are currently accepting submission from companies, such as 23andme, 
to review for approval, but other companies are holding back waiting for clear guidance from the 
FDA. These companies wanted to arm themselves with what information and data that the FDA 
is exactly looking for in approval and what types of products they may approve to be sold.  
 Thus, to assure the safety and effectiveness of DTC genetic tests, the FDA must 
promulgate regulations that will subject these tests to the same requirements as other medical 
devices, including test kits and LDTs.  By using the authority already granted to them to regulate 
medical devices under the FDCA, the FDA can protect the safety of consumers and advise 
companies on how to comply with regulations. The FDA has the most potential for providing a 
comprehensive regulatory scheme for DTC genetic testing services, and they should use the 
authority granted in them.  
As an alternative to promulgating regulations, the FDA could issue guidance documents 
that would give insight to DTC genetic testing companies on what the FDA prefers when it 
comes to how these tests are made, marketed, and monitored. However, guidance documents do 
not have the force of law that regulations do and are merely advisory. This means that companies 
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do not have to follow them, but can and should due to the deference given by the court.  
However, the FDA can avoid this issue by promulgating regulations that clearly layout the rules 
and steps for companies who are marketing DTC genetic tests.  
B. Risk Based Approval by the FDA 
A genetic test is only subject to the FDA regulation if it is a medical device and if it has 
an intended for use in the diagnosis of disease, or in the cure, mitigation, treatment, or prevention 
of disease. Therefore, it does not matter on whether a test is classified at nutrigenetic, 
pharmacogenetic, or predictive, as long as it has an intended use that is going to involve results 
that are used in the cure, mitigation, or treatment of any diseases. This will cover all three 
classifications of genetic tests because each tests offers information which a person will base a 
health related decision. For example, a test that determines a persons risk to developing lung 
cancer is a device because of the health related decisions a consumer can make based on the 
results. One aspect that the companies offer, ancestral, is not a device, and should remain to not 
be classified as one. These tests are educational and informative in nature only.  The FDA should 
classify each test based on its intended use to bring more tests in as medical devices. 
Next, the FDA should tailor the degree of regulation based on the condition being tested. 
The current medical device regulation under the FDCA allows for the FDA to require pre market 
approval for the proof of safety and effectiveness where necessary, but also allows for flexibility 
via the medical device classification system.  The FDA should use a risk-based approach to 
decide the level of regulation. This takes into account the type of service being offered and the 
results being given to the consumer. This approach was already recommended by the SACHS, 
and already utilized when it comes to IVDs and LDTs. The FDA must generate a risk based 
classification system for genetic tests that are offered directly to consumers. This should, as 
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explained in the LDT Guidance, coincide with the medical device classification system of the 
FDCA. The FDA can then amend the regulatory process based on the possible effects of each 
test, giving more regulation to higher risk tests. This means, as in the medical device statute that 
Class II genetic tests being offered to consumers will have to submit through the 501(k) and 
Class III will have to complete the extensive process for PMA. This will ensure the safety and 
effectives of each genetic test without over burdening the system.  
The one size fits all approach will not achieve the proper balance between the harms of 
that these genetic tests pose when placed in the consumers hands alone and promoting the 
development of genetic sciences in the United States. The risk based tiered approach is necessary 
and will be efficient in finding the proper balance for the regulation of genetic testing. The risk 
based approach will put companies on notice of what steps they must take to gain FDA approval 
and will allow the FDA to be in the loop about the intended uses of the products being sold. All 
of this, it is important to note, can occur under the existing regulatory framework, with some 
clarification on the part of the FDA. Consumer safety is right under the nose of the FDA, they 
just have to lay out the framework and enforce the regulations.  
The mission of 23andme is to help people “access, understand and benefit from the 
human genome,” and this should not be taken away simply because regulations are not clear. 149  
23andMe is unsure on what they have to do in order to be in compliance and approved by the 
FDA. Since being shut down, they have moved into the United Kingdom and Canada to sell their 
tests, and this almost seems like they are going to give up on the United States market. This, in 
turn, promotes the fear that America is going to be left behind in the genetic revolution. All of 
this can be avoided if the FDA used the power and authority it already has, and issues a risk 
based approach in regulations to ensure no genetic test marketed direct to consumers is falling 
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into any gaps.  
C.  Create a CLIA Genetic Test Specialty  
 
  The FDA cannot do it alone. CMS and FDA regulations complement one another and this 
should be taken advantage of. CLIA regulations focus on the quality of the clinical testing 
process, and the FDA address the safety and effectives of the test themselves. If the two agencies 
work together, there can be transparency for all genetic testing and assurance that the people who 
receive the test, the process the test goes through, and the product itself is safe and effective for 
public use. Companies like 23andMe already ensure that their lab partners adhere to the 
standards of CLIA. But when the CLIA standards are not meeting the need of the industry is 
where the problems occur. 
 The failure of CMS to create a genetic testing specialty has resulted in adequate oversight 
of the laboratories conducting genetic tests. As the demand in genetic testing continues to 
increase and more consumers are put at risk, there is a need to ensure that laboratories are 
property regulated. This is why CMS should follow through and create a genetic testing specialty 
under CLIA.  By creating a CLIA genetic testing specialty, proficiency standards for labs will be 
clear, as well as quality control standards. Genetic tests are not waived because they have the 
potential of risk and need skill behind them to be executed properly. As they are moderate or 
high complexity tests, they should be treated as other tests of that stature, and go through the 
necessary proficiency standards. CMS could then ensure the compliance of the labs if a specialty 
is created, and, in turn, ensure the accuracy and consistency of the tests before reaching the 
consumer.  
 This action, along with the FDA action to regulate will create a clear, transparent, and 
effective tool for regulation DTC genetic tests and help promote of the goals of the genetic 
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revolution.  
VI. CONCLUSION 
 The current system of regulation for the DTC genetic testing industry is not sufficient to 
ensure public safety from the harms of these tests.  Tests marked directly to consumers are 
falling into the gaps of unregulated and companies cannot comply because of the unclear 
regulatory system. Individuals should be able to take advantages of genetic science, but instead 
the United States is falling behind. The access to genetic information has the potential to save 
lives, but not if the results are misleading and inaccurate. The results, and the industry as a 
whole, must be regulated to ensure transparency, reliability, and accuracy. Companies and labs 
must clearly understand how the tests they produce are going to be regulated.  All tests should be 
regulated under a risk-based approach, with genetic tests falling under the medical device 
classification system of the FDCA, with the help of CMS regulation of laboratories. This 
approach will ensure the public can purchase tests from their homes that are safe and effective.  
 
